Financial Results, Conference Presentations, Stock Price Update, and Warrant Exercises - Research Report on Halozyme Therapeutics, Oxygen Biotherapeutics, ACADIA, MannKind, and ViroPharma
Editor Note: For more information about this release, please scroll to bottom.
13 Nov, 2013, 08:00 ET
NEW YORK, November 13, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Halozyme Therapeutics, Inc. (NASDAQ: HALO), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), MannKind Corporation (NASDAQ: MNKD), and ViroPharma Inc (NASDAQ: VPHM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Halozyme Therapeutics, Inc. Research Report
On November 8, 2013, Halozyme Therapeutics, Inc. (Halozyme Therapeutics) announced its Q3 2013 financial results. The Company's total revenues increased 200.2% YoY to $16.0 million during the quarter, which included $7.9 million in product sales of rHuPH20 active pharmaceutical ingredient for use in Herceptin SC manufacturing and $3.7 million in research services reimbursements from the collaborators. Net loss stood at $19.3 million or $0.17 per share in Q3 2013, compared to net loss of $20.0 million or $0.18 per share for Q3 2012. "This past quarter was remarkable for the European commercial launches of Herceptin® SC and HyQvia, each leveraging Halozyme's proprietary rHuPH20 technology to deliver more efficient treatment options," said Gregory I. Frost, Ph.D., President and CEO, Halozyme Therapeutics. "Furthermore, our development programs are advancing with recent maturing data from our Phase 1b PEGPH20 clinical trial supporting the hypothesis that patients with high hyaluronan tumor levels may benefit most from PEGPH20 therapy in the treatment of pancreatic cancer." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Oxygen Biotherapeutics, Inc. Research Report
On November 8, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) announced that the Company has received c.$6 million through the exercise of c.2.3 million warrants between November 4 2013 and November 6, 2013. "The exercise of these warrants increases our current cash on hand to approximately $8.4 million. Upon closing of the previously announced Phyxius Pharma transaction, we expect to be in a position to commence the Phase 3 FDA trial of levosimendan for the prevention and treatment of low cardiac output syndrome in heart surgery patients," stated Michael Jebsen, Oxygen Biotherapeutics' President, CFO and Interim CEO. According to the Company, the aforesaid warrants were issued by the Company in connection with its July 2013 Series C 8% Convertible Preferred Stock financing. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ACADIA Pharmaceuticals Inc. Research Report
On November 6, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) announced its Q3 2013 financial results. The Company posted net loss of $10.7 million or $0.12 per common share in Q3 2013, compared to $2.4 million or $0.04 per common share in Q3 2012. ACADIA's revenues stood at $240,000 in Q3 2013, compared to $3.5 million in Q3 2012. The marked differences in revenue was mainly due to the termination of ACADIA's collaboration with Meiji Seika Pharma in July 2012, which resulted in the recognition of the remaining $3.0 million of deferred revenue from this collaboration at that time. Commenting on the results, Uli Hacksell, Ph.D., ACADIA's CEO stated, "We remain focused on building value in our pimavanserin franchise and advancing our pipeline. During the third quarter of 2013, we continued to build on the strong momentum established in the first half of the year and made important progress in advancing our Parkinson's disease psychosis program with pimavanserin toward registration. We remain on track for a targeted NDA submission near the end of 2014. In parallel, we are finalizing study start-up activities for our Phase II trial in Alzheimer's disease psychosis that is scheduled for initiation this month." The Full Research Report on ACADIA Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MannKind Corporation Research Report
On November 7, 2013, MannKind Corporation announced its participation at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum, to be held at the Westin Grand Central in New York City, on Thursday, November 14, 2013, 11:30 a.m. ET. According to the Company, interested parties can access a link to the live webcast of the presentations from the News & Events section of MannKind Corporation's website. The Full Research Report on MannKind Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ViroPharma Inc Research Report
On November 8, 2013, ViroPharma Inc's (ViroPharma) stock rose 2.74% to end the day at $39.38. Over the past three trading periods, ViroPharma's stock slid 0.10%, compared to the NASDAQ composite which fell 0.52% during the same period. The Full Research Report on Viropharma Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article